Prosecution Insights
Last updated: April 19, 2026

Examiner: YAMASAKI, ROBERT J

Tech Center 1600 • Art Units: 1657

This examiner grants 67% of resolved cases

Performance Statistics

67.2%
Allow Rate
+7.2% vs TC avg
576
Total Applications
+43.2%
Interview Lift
1286
Avg Prosecution Days
Based on 540 resolved cases, 2023–2026

Rejection Statute Breakdown

2.5%
§101 Eligibility
15.1%
§102 Novelty
36.0%
§103 Obviousness
29.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17416480 ENZYMATIC HEXOSAMINIDATION OF LACTOSE Non-Final OA BASF SE
17908704 Zika Virus Polypeptides Final Rejection Mayo Foundation for Medical Education and Research
17658009 GENERATION OF CELL-BASED PRODUCTS FOR CONSUMPTION THAT COMPRISE PROTEINS FROM EXOTIC, ENDANGERED, AND EXTINCT SPECIES Non-Final OA Upside Foods, Inc.
18571437 RECOMBINANT YEAST SACCHAROMYCES BOULARDII FOR PRODUCING NEOAGAROOLIGOSACCHARIDES AND USE THEREOF Non-Final OA KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
18288728 NOVEL PROTEIN HAVING METHANE OR BUTANE OXIDATION ACTIVITY Non-Final OA KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
17916087 SEQUENCING-BASED POPULATION SCALE SCREENING Final Rejection MASSACHUSETTS INSTITUTE OF TECHNOLOGY
18682548 TARGETING 3-KETODIHYDROSPHINGOSINE REDUCTASE (KDSR) IN CANCER Non-Final OA UNIVERSITY OF MASSACHUSETTS
18313164 DISPERSED INTEGRATION OF RENEWABLE CHEMICAL PRODUCTION INTO EXISTING OIL, GAS, PETROLEUM, AND CHEMICAL PRODUCTION AND INDUSTRIAL INFRASTRUCTURE Non-Final OA LanzaTech, Inc.
18968703 CONCRETE COUPON FOR RECOVERY OF BIOLOGICAL AGENTS Final Rejection The Government of the United States of America, as represented by the Secretary of Homeland Security
18018230 MATERIALS AND METHODS FOR MAKING SEXUAL STAGE PLASMODIUM PARASITES Non-Final OA The Penn State Research Foundation
18571661 RECOMBINANT CUTINASE EXPRESSION Non-Final OA Novozymes A/S
18597329 Soluble Guanylyl Cyclase (GC1) Mimetic Polypeptides and Methods of Use Thereof Non-Final OA Rutgers, the State University of New Jersey
18680251 METHODS OF PRODUCING FUNCTIONALIZED POWDER PARTICLES Non-Final OA KREMENAK NANOTECH, INC.
17781796 Method for Diagnosing Cancer, Cancer Diagnosis Composition, Cancer Diagnosis Kit, Method for Evaluating State of Cancer, and Method for Screening Agents for Preventing and/or Treating Cancer Final Rejection Kyushu University, National University Corporation
17415010 METHOD OF ENCODING DATA ON A POLYNUCLEOTIDE STRAND Non-Final OA Oxford Nanopore Technologies PLC
18559264 USES AND METHODS FOR ELEMENTOMIC CHARACTERIZATION ANALYSIS IN DIAGNOSIS AND PROGNOSIS OF MEDICAL DISEASES AND CONDITIONS Non-Final OA SHANGHAITECH UNIVERSITY
18614283 CELL CULTURE LASER PHOTOABLATION Final Rejection EditCo Bio, Inc.
17915146 COLLAGENASE AGENT AND USE THEREOF Non-Final OA AMANO ENZYME INC.
18163084 EXPRESSION OF THE HUMAN LEKTI GENE FROM THE CHROMOSOME OF STAPHYLOCOCCUS EPIDERMIDIS Non-Final OA Azitra Inc
18562266 SELECTIVE LYSIS OF MAMMALIAN EUKARYOTIC CELLS AND VISUALIZATION OF VIABLE BACTERIAL CELLS Non-Final OA Aman RUSSOM
18290568 METHODS AND SYSTEMS FOR GENERATING BIOLOGICAL MOLECULES Non-Final OA MACHINE BIO INC.
17768896 EFFICIENT RNA SWITCHES AND RELATED EXPRESSION SYSTEMS Non-Final OA THE SCRIPPS RESEARCH INSTITUTE
18547466 IN SITU METHANOGENIC RECOVERY FROM WASTE PRODUCTS Final Rejection Transworld Technologies Inc.
17629322 Increasing Long-Sequence Yields In Template-Free Enzymatic Synthesis of Polynucleotides Final Rejection DNA Script
17977341 ASSESSING IMMUNE SYSTEM FUNCTION AND STATUS Final Rejection Travera, Inc.
17642054 METHOD FOR THE PRODUCTION OF RAAV AND METHOD FOR THE IN VITRO GENERATION OF GENETICALLY ENGINEERED, LINEAR, SINGLE-STRANDED NUCLEIC ACID FRAGMENTS CONTAINING ITR SEQUENCES FLANKING A GENE OF INTEREST Non-Final OA UNIVERSITÄT BIELEFELD
17419893 A METHOD FOR ASSEMBLING CIRCULAR AND LINEAR DNA MOLECULES IN AN ORDERED MANNER Final Rejection UNIVERSITY OF MARLYLAND, BALTIMORE COUNTY

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month